TY - JOUR
T1 - Clinical and Pathological Benefits of Scallop-Derived Plasmalogen in a Novel Mouse Model of Alzheimer's Disease with Chronic Cerebral Hypoperfusion
AU - Feng, Tian
AU - Hu, Xinran
AU - Fukui, Yusuke
AU - Bian, Zhihong
AU - Bian, Yuting
AU - Sun, Hongming
AU - Takemoto, Mami
AU - Yunoki, Taijun
AU - Nakano, Yumiko
AU - Morihara, Ryuta
AU - Abe, Koji
AU - Yamashita, Toru
N1 - Funding Information:
This work was partly supported by a Grant-in-Aid for Scientific Research (B) 25293202, (C) 15K09316 and Challenging Research 15K15527 and Young Research 15K21181, and by Grants-in-Aid from the Research Committees (Mizusawa H, Nakashima K, Nishizawa M, Sasaki H, and Aoki M) from the Ministry of Health, Labour and Welfare of Japan. We thank Takehiko Fujino (Institute of Rheological Functions of Food, Fukuoka, Japan) for kindly offering highly pure scallop-derived plasmalogen and for excellent technical assistance.
Publisher Copyright:
© 2022 The authors.
PY - 2022
Y1 - 2022
N2 - Background: The oral ingestion of scallop-derived plasmalogen (sPlas) significantly improved cognitive function in Alzheimer's disease (AD) patients. Objective: However, the effects and mechanisms of sPlas on AD with chronic cerebral hypoperfusion (CCH), a class of mixed dementia contributing to 20-30% among the dementia society, were still elusive. Methods: In the present study, we applied a novel mouse model of AD with CCH to investigate the potential effects of sPlas on AD with CCH. Results: The present study demonstrated that sPlas significantly recovered cerebral blood flow, improved motor and cognitive deficits, reduced amyloid-β pathology, regulated neuroinflammation, ameliorated neural oxidative stress, and inhibited neuronal loss in AD with CCH mice at 12 M. Conclusion: These findings suggest that sPlas possesses clinical and pathological benefits for AD with CCH in the novel model mice. Furthermore, sPlas could have promising prevention and therapeutic effects on patients of AD with CCH.
AB - Background: The oral ingestion of scallop-derived plasmalogen (sPlas) significantly improved cognitive function in Alzheimer's disease (AD) patients. Objective: However, the effects and mechanisms of sPlas on AD with chronic cerebral hypoperfusion (CCH), a class of mixed dementia contributing to 20-30% among the dementia society, were still elusive. Methods: In the present study, we applied a novel mouse model of AD with CCH to investigate the potential effects of sPlas on AD with CCH. Results: The present study demonstrated that sPlas significantly recovered cerebral blood flow, improved motor and cognitive deficits, reduced amyloid-β pathology, regulated neuroinflammation, ameliorated neural oxidative stress, and inhibited neuronal loss in AD with CCH mice at 12 M. Conclusion: These findings suggest that sPlas possesses clinical and pathological benefits for AD with CCH in the novel model mice. Furthermore, sPlas could have promising prevention and therapeutic effects on patients of AD with CCH.
KW - Alzheimer's disease
KW - amyloid-β pathology
KW - chronic cerebral hypoperfusion
KW - neural oxidative stress
KW - neuroinflammation
KW - scallop-derived plasmalogen
UR - http://www.scopus.com/inward/record.url?scp=85129322496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129322496&partnerID=8YFLogxK
U2 - 10.3233/JAD-215246
DO - 10.3233/JAD-215246
M3 - Article
C2 - 35253748
AN - SCOPUS:85129322496
SN - 1387-2877
VL - 86
SP - 1973
EP - 1982
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 4
ER -
